Shield Therapeutics appoints new Non-Executive Director
Francesca Morgan
RNSNewswire
10:49, 26th June 2020

Pharmaceutical company, Shield Therapeutics (LON: STX FOLLOW), has announced the appointment of Dr. Christian Schweiger as a Non-Executive Director with immediate effect.

Dr. Schweiger co-founded Shield in 2008 and was more recently employed by the company between March 2016 and April 2017 in a senior medical science capacity.

As a senior medical affairs and clinical development executive, the group said Dr. Schweiger has ‘substantial experience working with both large and small pharmaceutical companies.’

Shares in Shield Therapeutics closed at 91.5p on Thursday afternoon.

Dr Schweiger is also Lecturing Professor in Pharmaceutical Medicine at the University of Essen and ‘actively working’ with different international patient and professional associations.

"I am delighted that Christian has agreed to join the board of Shield bringing his previous knowledge of the Company and Feraccru, and also his extensive experience in medical affairs and clinical development,” said Hans Peter Hasler, Chairman of Shield Therapeutics.

Schweiger currently owns 4,114,300 ordinary shares of 1.5p each in STX representing 3.5% of the Company's issued share capital, and therefore is not considered to be independent.

Follow News & Updates from Shield Therapeutics here: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Comments
info
Login or register to post comments

Recent Articles
Watchlist